Login to Your Account



Financings Roundup

Is Tau How? GMS Bets $31.5M on Alzheimer's Phase III Effort

By Randy Osborne
Staff Writer

Wednesday, November 21, 2012

After years of throwing themselves futilely against the beta amyloid wall, companies trying for Alzheimer's disease (AD) therapies are turning away, hoping to find a door that opens on a way to modify the devastating condition.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription